LDLR and pancreatic neoplasm: To investigate whether LDLR is a suitable candidate for targeting PDAC in patients, we first performed an in silico analysis of the LDLR mRNA expression profile in primary and metastatic pancreatic tumor samples (n = 728 and n = 76, respectively) compared to normal adjacent pancreas (n = 96).